Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.
暂无分享,去创建一个
M. Price | J. Curtis | Yongfei Wang | A. Goldsweig | F. Masoudi | P. Varosy | K. Minges | D. Gibson | D. Friedman | U. Daimee | S. Doshi | James V Freeman | A. Higgins | Chengan Du | Lucy Pereira | Vivek Y. Reddy | James V. Freeman
[1] Christopher R. Ellis,et al. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE) , 2021, Circulation.
[2] V. Reddy,et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device , 2021, Circulation.
[3] P. Neužil,et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. , 2020, Journal of the American College of Cardiology.
[4] P. Stella,et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.
[5] M. Price,et al. The NCDR Left Atrial Appendage Occlusion Registry. , 2020, Journal of the American College of Cardiology.
[6] S. Kische,et al. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage , 2019, Circulation. Arrhythmia and electrophysiology.
[7] V. Reddy,et al. EWOLUTION of Watchman Left Atrial Appendage Closure to Patients With Contraindication to Oral Anticoagulation. , 2019, Circulation. Arrhythmia and electrophysiology.
[8] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.
[9] V. Reddy,et al. Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes , 2018, Circulation.
[10] Saibal Kar,et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.
[11] J. Messenger,et al. Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.
[12] W. O’Neill,et al. Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.
[13] M. Price,et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. , 2017, Heart rhythm.
[14] S. Kische,et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.
[15] Saibal Kar,et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.
[16] M. Price,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.
[17] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[18] Frederick T. Han,et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. , 2013, Journal of the American College of Cardiology.
[19] J. Messenger,et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.
[20] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[21] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[22] S. Gallagher,et al. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance , 2011, Heart.
[23] S. Yakubov,et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. , 2011, Heart rhythm.
[24] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[25] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[26] P. Teirstein,et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. , 2009, JACC. Cardiovascular interventions.
[27] Stef van Buuren,et al. Multiple imputation of discrete and continuous data by fully conditional specification , 2007 .
[28] K. Chandrasekaran,et al. Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation. , 2006, American heart journal.
[29] J. Odell,et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.
[30] N. Ammash,et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographics tudy , 1995 .